AIP
MBRX icon

Almanack Investment Partners’s Moleculin Biotech MBRX Stock Holding History

Almanack Investment Partners’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed -$1K – 763
2022
Q3 		$1K Buy
+3
New +$1.74K ﹤0.01% 811

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Almanack Investment Partners's MBRX Position: Q4 2022 in Review

Almanack Investment Partners sold out of Moleculin Biotech (MBRX) in Q4 2022, closing a stake of 3 shares — an estimated $1K sold.

Almanack Investment Partners first reported a position in MBRX in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 22 funds tracked by Wall St. Rank hold MBRX as of Q4 2022.

  • Almanack Investment Partners reported no remaining Moleculin Biotech position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 3 Moleculin Biotech shares in Q4 2022, an estimated $1K.
  • Almanack Investment Partners first reported a position in Moleculin Biotech in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Moleculin Biotech position peaked at $1K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.